Insilico Medicine (“Insilico”), a clinical-stage, generative AI-driven drug discovery company, today announced the nomination of ISM3830, a potential best-in-class, oral available, highly selective CBLB inhibitor with AI-empowered novel scaffold, as a preclinical candidate against multiple advanced tumors.  

Prolonged exposure to hot weather and direct sunlight can lead to heat exhaustion and skin irritation, which reduces the productivity of outdoor workers and increases health risks. This study has developed a polylactic acid/boron nitride nanosheet composite fabric by electrospinning. Being selectively modified for hydrophilicity, the fabric has combined passive radiative cooling, thermal conductivity and directional sweat wicking to improve thermal comfort in outdoor environments. Compared to conventional cotton fabrics, the composite fibric exhibits excellent solar reflectance (96%) and infrared heat emissivity (93%), along with high thermal conductivity (0.38 W·m^-1 K^-1). In outdoor experiments, the composite fabric lowers skin temperature by 2.0 °C under direct sunlight during the day and by 3.8 °C at night relative to bare skin. The composite fabric features a directional perspiration function and an impressive sweat evaporation rate of 1.67 g·h⁻¹, which can efficiently transport sweat and heat to the fiber membrane surface to keep the skin dry and cool. This work should advance human thermal management strategies for high-temperature outdoor environments.

A new study by researchers at Shinshu University highlights the essential role of gut microbiota in livestock health and productivity. The researchers show how probiotics, prebiotics, and synbiotics can safely enhance growth and immunity, and balance the growth of intestinal microbes, offering practical alternatives to antibiotics. As global restrictions on antibiotic use intensify, the findings support sustainable livestock management and contribute to reducing antimicrobial resistance risks.

Insilico Medicine (“Insilico”), a clinical-stage, generative AI-driven drug discovery company, today announced its participation in NeurIPS 2025, to be held in San Diego, USA, from December 2–7, 2025. Led by Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine, and Petrina Kamya, PhD, Global Head of AI Platforms, Insilico’s experienced team will participate in the conference.

In a recent pioneering study, researchers at Insilico Medicine ("Insilico"), a generative artificial intelligence (AI)-driven clinical-stage biotechnology company, harnessed its AI-driven generative chemistry platform, Chemistry42, to design a novel, first-in-class PROTAC targeting PKMYT1, D16-M1P2, which employs a dual mechanism of action—inducing PKMYT1 degradation while directly inhibiting its kinase activity. This innovative strategy holds promise for overcoming limitations of existing inhibitors, such as poor selectivity and acquired resistance, and to effectively target both the catalytic and non-catalytic functions of PKMYT1. As a result, the PROTAC demonstrates the potential for a more selective, potent, and durable therapeutic effect.

An international research team led by RMIT University have created tiny particles, known as nanodots, made from a metallic compound that can kill cancer cells while leaving healthy cells largely unharmed.

While this work is still at the cell-culture stage – it hasn’t been tested in animals or people – it points to a new strategy for designing cancer treatments that exploit cancer’s own weaknesses.